Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO

Mizrahi, Romina; Agid, Ofer; Borlido, Carol; Suridjan, Ivonne; Rusjan, Pablo; Houle, Sylvain; Remington, Gary; Wilson, Alan A.; Kapur, Shitij

doi:10.1016/j.schres.2011.05.005

Cited by 79 publications

(56 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an attempt to solve this problem, we compared the present BP ND values with baseline (resting) BP ND data from a previous study in patients with schizophrenia. 63 We found no significant difference between the baseline BP ND reported in our previous study 19 and the ones observed under cognitive activation in the present study in all of the ROIs tested (group F 1,19 = 0.735, p = 0.40; region F 4,16 = 21.821, p < 0.001; group × region F 4,16 = 1.014, p = 0.43). In addition, the lack of difference in [ 11 C]-(+)-PHNO binding among the groups may reflect the small DA releasing effect of this particular cognitive task or the lack of participants' own resting state baselines, which may have translated into a statistically nonsignificant difference among the groups.…”

Section: Limitationscontrasting

confidence: 72%

Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task

Suridjan

Rusjan²,

Addington³

et al. 2013

J Psychiatry Neurosci

Self Cite

View full text Add to dashboard Cite

Section: Limitationscontrasting

confidence: 72%

Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task

Suridjan

Rusjan²,

Addington³

et al. 2013

J Psychiatry Neurosci

Self Cite

View full text Add to dashboard Cite

“…PET data were used to construct a time-activity curve for the cerebellum, a region of minimal D 2/3 R binding, which was used as the reference region as in previous studies (Boileau et al, 2012;Ginovart et al, 2007;Matuskey et al, 2014Matuskey et al, , 2015Matuskey et al, , 2016Mizrahi et al, 2011;Payer et al, 2014;Searle et al, 2010). A summed image (0-10 min after injection) was created from the motion-corrected PET data and registered to the participant's MR image, which was nonlinearly registered to an MR template in Montreal Neurological Institute (MNI) space.…”

Section: Methodsmentioning

confidence: 99%

Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO

Gaiser

Gallezot

Worhunsky

et al. 2016

Neuropsychopharmacol

View full text Add to dashboard Cite

Most prior work with positron emission tomography (PET) dopamine subtype 2/3 receptor (D 2/3 R) non-selective antagonist tracers suggests that obese (OB) individuals exhibit lower D 2/3 Rs when compared with normal weight (NW) individuals. A D 3 -preferring D 2/3 R agonist tracer, [ 11 C](+)PHNO, has demonstrated that body mass index (BMI) was positively associated with D 2/3 R availability within striatal reward regions. To date, OB individuals have not been studied with [ 11 C](+)PHNO. We assessed D 2/3 R availability in striatal and extrastriatal reward regions in 14 OB and 14 age-and gender-matched NW individuals with [ 11 C](+)PHNO PET utilizing a high-resolution research tomograph. Additionally, in regions where group D 2/3 R differences were observed, secondary analyses of 42 individuals that constituted an overweight cohort was done to study the linear association between BMI and D 2/3 R availability in those respective regions. A group-by-brain region interaction effect (F 7, 182 = 2.08, p= 0.047) was observed. Post hoc analyses revealed that OB individuals exhibited higher tracer binding in D 3 -rich regions: the substantia nigra/ventral tegmental area (SN/VTA) (+20%; p = 0.02), ventral striatum (VST) (+14%; po0.01), and pallidum (+11%; p = 0.02). BMI was also positively associated with D 2/3 R availability in the SN/VTA (r = 0.34, p = 0.03), VST (r = 0.36, p = 0.02), and pallidum (r = 0.30, p = 0.05) across all subjects. These data suggest that individuals who are obese have higher D 2/3 R availability in brain reward regions densely populated with D 3 Rs, potentially identifying a novel pharmacologic target for the treatment of obesity.

show abstract

“…Cariprazine is distinct from other atypical antipsychotics as it shows greater in vitro affinity for the D 3 versus D 2 receptor with almost 10-fold higher D 3 receptor selectivity (Kiss et al, 2010). In vivo, cariprazine demonstrates high and balanced occupancy at both D 2 and D 3 receptors (Kiss et al, 2012); evidence suggests that other antipsychotics may not show significant occupancy of the D 3 receptor in vivo at clinically relevant doses (Graff-Guerrero et al, 2009;McCormick et al, 2010;Mizrahi et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial

Sachs

Greenberg²,

Starace³

et al. 2015

Journal of Affective Disorders

102

View full text Add to dashboard Cite

show abstract

Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO

Cited by 79 publications

References 37 publications

Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task

Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task

Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO

Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial

Contact Info

Product

Resources

About